Among Japanese patients with tumor PD-L1 expression level of 1% or more, we found no clear difference in DFS between the nivolumab and placebo groups (median 29.67 and 25.95 months, HR 1.10, 95% CI 0.31–3.92) (Fig. 2). Here, CD274 is linked to neoplasm.